Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785819 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
A Phase 2 study, sponsored by Veralox Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT05785819 is a Phase 2 study that was terminated before completion, run by Veralox Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT05785819, a Phase 2 study, was terminated before completion, sponsored by Veralox Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Interventions
- DRUG Placebo
- DRUG VLX-1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2025-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05785819
The ClinicalTrials.gov registry entry for NCT05785819 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veralox Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05785819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05785819 about?
NCT05785819 is a clinical study titled "A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia". The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or p...
What is the current status of trial NCT05785819?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2023-09-26. Estimated completion is 2025-11-17.
What interventions are being tested in trial NCT05785819?
The interventions under investigation include: Placebo (DRUG), VLX-1005 (DRUG).
Who is sponsoring clinical trial NCT05785819?
This trial is sponsored by Veralox Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.